Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021
LW-02 Immunopheresis® therapy shown to be safe and well-tolerated in treating late-stage cancer patients who failed multiple lines of standard...